| Jun 27 |
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
|
| Jun 17 |
BioRestorative Therapies regains compliance, reports Q1 2024 results
|
| Jun 17 |
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
|
| Jun 13 |
BioRestorative spikes on talks for a potential licensing pact
|
| Jun 13 |
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
|
| Jun 11 |
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
|
| Jun 4 |
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
|
| May 27 |
BioRestorative Therapies receives Nasdaq notice of non-compliance
|
| May 24 |
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
|
